Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis

被引：0
|
作者：
Spessotto, Caroline [1 ]
Cavalli, Hanaie [2 ]
Eboni, Audred [3 ]
Machado, Rafael [4 ]
Mousquer, Analara [5 ]
Palazzo, Lara [4 ]
Finkelsztejn, Alessandro [4 ]
Goncalves, Marcos [3 ]
Sato, Henry [2 ]
Siquineli, Fabio [5 ]
Fragoso, Yara [2 ]
机构：
[1] Univ Metropolitana Santos, Sao Paulo, Brazil
[2] Inst Neurol Curitiba, Curitiba, Parana, Brazil
[3] Ctr Hosp Unimed Joinville, Joinville, Brazil
[4] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[5] Univ Reg Blumenau, Blumenau, Brazil
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
57
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [41] No difference among disease-modifying drugs for the long-term treatment of multiple sclerosis
    Rolak, Loren A.
    Bejaoui, Khemissa
    Matti, Charmaine
    Foss, Dawn
    ANNALS OF NEUROLOGY, 2008, 64 : S59 - S59
  • [42] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    PLOS ONE, 2017, 12 (10):
  • [43] Adherence to disease-modifying therapies in patients with multiple sclerosis
    Koltuniuk, Aleksandra
    Rosinczuk, Joanna
    PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 1557 - 1565
  • [44] Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis
    Lin, ATH
    Clements, PJ
    Furst, DE
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2003, 29 (02) : 409 - +
  • [45] Disease-modifying drugs prevent long-term progression in multiple sclerosis patients
    Bergamaschi, R.
    Tavazzi, E.
    Quaglini, S.
    Poloni, G.
    Romani, A.
    Persico, A.
    Crivelli, P.
    Crabbio, M.
    Montomoli, C.
    Di Stefano, A. L.
    Bastianello, S.
    Cosi, V.
    MULTIPLE SCLEROSIS, 2007, 13 : S90 - S90
  • [46] Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis
    Desai, Rishi J.
    Mahesri, Mufaddal
    Gagne, Joshua J.
    Hurley, Eimir
    Tong, Angela
    Chitnis, Tanuja
    Minden, Sarah
    Spettell, Claire M.
    Matlin, Olga S.
    Shrank, William H.
    Choudhry, Niteesh K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (01): : 113 - 121
  • [47] Effect of disease-modifying treatment on coronavirus disease 2019 vaccination in patients with multiple sclerosis
    D'haeseleer, M.
    Van Remoortel, A.
    D'hooghe, M.
    Della Faille, L.
    Nagels, G.
    Van Schependom, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 429 - 430
  • [48] Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis
    Bruno, Antonio
    Annovazzi, Pietro
    Clerico, Marinella
    Cocco, Eleonora
    Conte, Antonella
    Marfia, Girolama Alessandra
    Salvetti, Marco
    Tomassini, Valentina
    Clerici, Valentina Torri
    Totaro, Rocco
    Dolcetti, Ettore
    Centonze, Diego
    CURRENT NEUROPHARMACOLOGY, 2024,
  • [49] Treatment Patterns in Disease-Modifying Therapy for Patients With Multiple Sclerosis in the United States
    Bonafede, Machaon M.
    Johnson, Barbara H.
    Wenten, Made
    Watson, Crystal
    CLINICAL THERAPEUTICS, 2013, 35 (10) : 1501 - 1512
  • [50] Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs
    Lu, E.
    Dahlgren, L.
    Sadovnick, A. D.
    Sayao, A.
    Synnes, A.
    Tremlett, H.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 460 - 467
12345